Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Post-infectious encephalomyelitis.

Cornelia Mihai1, Burk Jubelt

  • 1SUNY Upstate Medical University, 750 E. Adams Street, Syracuse, NY 13210, USA. mihaic@upstate.edu.

Current Neurology and Neuroscience Reports
|November 3, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis.

The New England journal of medicine·2018
Same author

Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis.

Contemporary clinical trials·2016
Same author

Factors associated with benign multiple sclerosis in the New York State MS Consortium (NYSMSC).

BMC neurology·2016
Same author

Enterovirus/picornavirus infections.

Handbook of clinical neurology·2014
Same author

Infectious myelitis.

Current neurology and neuroscience reports·2012
Same author

Interleukin-33 upregulation in peripheral leukocytes and CNS of multiple sclerosis patients.

Clinical immunology (Orlando, Fla.)·2011
Same journal

The Noradrenergic Brain in Parkinson's Disease.

Current neurology and neuroscience reports·2026
Same journal

Mapping the Silent Onset of Parkinson's Disease: Monoamine Imaging in the Era of the Race for Preclinical Intervention.

Current neurology and neuroscience reports·2026
Same journal

Functional and Structural Brain Imaging Correlates of Treatment Response in Functional Movement Disorder.

Current neurology and neuroscience reports·2026
Same journal

Astrocytopathy in Wernicke Encephalopathy and Neuromyelitis Optica Spectrum Disorder. Pathogenic Differences With Occasional Clinical and Neuroimaging Overlap. A Review.

Current neurology and neuroscience reports·2026
Same journal

When is the Radiologically Isolated Syndrome already Multiple Sclerosis According to the 2024 McDonald Criteria?

Current neurology and neuroscience reports·2026
Same journal

Assessment and Management of Post-traumatic Headache.

Current neurology and neuroscience reports·2026
See all related articles

Post-infectious encephalomyelitis (PIEM) and acute disseminated encephalomyelitis (ADEM) are demyelinating central nervous system disorders. Clinical and MRI features help differentiate these from multiple sclerosis, with methylprednisolone often effective for treatment.

Area of Science:

  • Neurology
  • Immunology
  • Neuroimmunology

Background:

  • Post-infectious encephalomyelitis (PIEM) and acute disseminated encephalomyelitis (ADEM) are primary demyelinating disorders of the central nervous system.
  • These conditions are often confused with multiple sclerosis (MS) and Devic's disease.
  • Distinguishing between ADEM/PIEM and the initial presentation of MS can be challenging due to the lack of specific diagnostic tests.

Purpose of the Study:

  • To clarify the distinction between PIEM and ADEM.
  • To outline the diagnostic challenges in differentiating PIEM/ADEM from other demyelinating diseases.
  • To discuss the therapeutic strategies for PIEM/ADEM.

Main Methods:

  • Review of clinical and magnetic resonance imaging (MRI) features.

Related Experiment Videos

  • Comparison of diagnostic criteria for ADEM, PIEM, and MS.
  • Analysis of treatment outcomes for various therapeutic interventions.

    • Main Results:

    • PIEM follows a known infection, while ADEM lacks a clear antecedent infection.
    • Clinical and MRI findings can differentiate PIEM/ADEM from relapsing neurological diseases like MS.
    • Methylprednisolone is a common and often effective treatment.

    Conclusions:

    • Accurate differentiation of PIEM/ADEM from other demyelinating disorders is crucial for appropriate management.
    • While spontaneous recovery occurs, most patients benefit from treatments like methylprednisolone.
    • Plasma exchange and intravenous immunoglobulin are effective alternatives when initial therapy fails.